Trial of Pimavanserin in Dementia-Related Psychosis.

@article{Tariot2021TrialOP,
  title={Trial of Pimavanserin in Dementia-Related Psychosis.},
  author={Pierre N. Tariot and Jeffrey L. Cummings and Maria Soto-martin and Clive Ballard and Deniz Erten‐Lyons and David L. Sultzer and Davangere P. Devanand and Daniel Weintraub and Bradley W. McEvoy and James M. Youakim and Srdjan Stankovic and Erin Pennock Foff},
  journal={The New England journal of medicine},
  year={2021},
  volume={385 4},
  pages={
          309-319
        }
}
BACKGROUND Patients with dementia due to neurodegenerative disease can have dementia-related psychosis. The effects of the oral 5-HT2A inverse agonist and antagonist pimavanserin on psychosis related to various causes of dementia are not clear. METHODS We conducted a phase 3, double-blind, randomized, placebo-controlled discontinuation trial involving patients with psychosis related to Alzheimer's disease, Parkinson's disease dementia, dementia with Lewy bodies, frontotemporal dementia, or… 
Relapse in Dementia-related Psychosis and Clinical Decisions
TLDR
A randomized medication withdrawal clinical trial design allows assessment of relapse risk after discontinuation and can provide initial information on longer-term safety of therapy for dementia-related psychosis.
Advances in dementia with Lewy bodies
  • M. Armstrong
  • Medicine, Psychology
    Therapeutic advances in neurological disorders
  • 2021
TLDR
Recent advances in dementia with Lewy bodies include publication of updated diagnostic criteria and recognition of prodromal DLB states, including mild cognitive impairment, delirium-onet, and psychiatric-onset forms.
NDT_A_324145 3791..3818
TLDR
This review evaluates how medications used to treat PD affect QTc interval from literature indexed in the PubMed and Embase databases and concludes that pimavanserin was approved by the US Food and Drug Administration in 2016 and remains the only FDA-approved medication available to treat hallucinations and delusions associated with PDP.
QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson’s Disease Psychosis: A Narrative Review
TLDR
This review evaluates how medications used to treat PDP affect QTc interval from literature indexed in the PubMed and Embase databases and concludes that pimavanserin was approved by the US Food and Drug Administration in 2016 and remains the only FDA-approved medication to treat hallucinations and delusions associated with PDP.
Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
TLDR
Aducanumab, a monoclonal antibody recently approved by the Food and Drug Administration, was able to reduce Aβ accumulation and slow the progression of cognitive impairment, and was claimed to have an effect on the second hallmark of AD, decreasing the level of phospho-Tau evaluated in cerebrospinal fluid and by positron emission tomography.
Executive Summary of the 2021 International Conference of Korean Dementia Association: A Report From the Academic Committee of the Korean Dementia Association
TLDR
Through the second international conference of the Korean Dementia Association (KDA), researchers from all over the world have participated in the exchange of opinions with KDA members on the most up-to-date topics and this will be an important milestone to widen the latest knowledge in the research of AD’s diagnosis, therapeutics, pathogenesis.
Long-term outcomes with pimavanserin for psychosis in clinical practice
The role of basket trials in drug development for neurodegenerative disorders
TLDR
Basket trials may increase drug development efficiency by reducing redundancy in trial implementation, enhancing recruitment, sharing placebo groups, and using biomarkers relevant to the mechanism of action of the treatment across NDDs.
...
...